Drug-Eluting Stents

HeartDrug

Volumn 3, Issue 4, 2003, Pages 203-213

  Liistro, Francesco ^a   Bolognese, Leonardo ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Antiproliferative agents; Drug eluting stents; Restenosis

Indexed keywords

ABT 578; ANGIOPEPTIN; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIPROLIFERATIVE DRUG; BATIMASTAT; DACTINOMYCIN; DEXAMETHASONE; DRUG; ESTRADIOL; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; POLY(LACTIDE CO SIGMA CAPROLACTONE); POLYBUTYL METHACRYLATE; POLYETHYLENE VINYL ACETATE; POLYMER; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; HUMAN; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STENOSIS; TREATMENT OUTCOME;

EID: 1242284279     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075706     Document Type: Review

References (45)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
3. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-1436.
4. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG: Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: A controlled study. J Am Coll Cardiol 2000;35:1554-1559.
5. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD: Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: A 20-year experience. J Am Coll Cardiol 2001;38:409-414.
6. Hoffmann R, Mintz GS, Reineke T, Kent KM, Pichard AD, Satler LF, Hanrath P, Leon MB: Lesion-to-lesion relationship of the restenosis process after placement of coronary stents. Catheter Cardiovasc Interv 2000;51:266-272.
7. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schomig A: Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-1288.
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
9. Edelman ER, Rogers C: Pathobiologic responses to stenting. Am J Cardiol 1998;81:4E-6E.
10. Braun-Dullaeus RC, Mann MJ, Dzau VJ: Cell cycle progression: New therapeutic target for vascular proliferative disease. Circulation 1998;98:82-89.
11. Grube E: Final Tacrolimus Outcomes in Native Coronaries and Saphenous Vein Grafts: PRESENT and EVIDENT. Presented at the Scientific Sessions of the American College of Cardiology, Drug-Eluting Stent Symposium, Chicago, March 29, 2003.
12. Herdeg C, Oberhoff M, Karsch KR: Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998;3:197-199.
13. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME: TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
14. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
15. Stone GW: Taxus IV clinical results. Presented at the TCT meeting, Washington, September 2003.
16. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME: TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
17. Dawkins KD, Investigators ftTV: TAXUS VI: 30 day results. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, May 2003.
18. Abizaid A: WISDOM Registry update. Presented at the TCT meeting, Washington, September 2003.
19. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS: A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
20. Gershlick A, Descheerder I, Chevalier B, Camezind E, Gommeaux A, Vrints C, Reifart N, Missault L, Goy J, Brinker J, Stephens Lloyd A, Heldman A: Local drug delivery to inhibit coronary artery restenosis. Data from ELUTES (evaluation of paclitaxel eluting stent) clinical trial. Circulation 2001;104:II-416.
21. Gershlick A, De Scheerder I, Chevalier B, Investigators fE: Long-term follow-up in the ELUTES clinical study. Am J Cardiol 2002;90:1H.
22. Grube E: Delivery 2 study. Final results presented at the TCT meeting, Washington, 2003.
23. Marx SO, Jayaraman T, Go LO, Marks AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-417.
24. Marx SO, Marks AR: Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855.
25. Serruys PW, Regar E, Carter AJ: Rapamycin eluting stent: The onset of a new era in interventional cardiology. Heart 2002;87:305-307.
26. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.
27. Leon MB, Moses JW, Popma JJ, Fishel T, Wong SC, Midei M, Douglas J, Lambert C, Mooney M, Teirstein P, Kuntz RE: A multicenter randomized clinical study of the sirolimus-eluting stent in native coronary lesions: Angiographic results (abstract). Circulation 2002;106:II-393.
28. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
29. Di Mario C, Investigators ftSB: The SIRIUS Bifurcations Study: 6-months clinical and angiographic results. Presented at the Scientific Sessions of the American College of Cardiology, Drug-Eluting Stent Symposium, Chicago, March 29, 2003.
30. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, de Feyter P, Vos J, Foley DP, Ligthart JM, Popma JJ, Serruys PW: Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 2003;41:184-189.
31. Saia F, Lemos PA, Sianos G, Degertekin M, Lee CH, Arampatzis CA, Hoye A, Tanabe K, Regar E, van der Giessen WJ, Smits PC, de Feyter P, Ligthart J, van Domburg RT, Serruys PW: Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. Am J Cardiol 2003;92:200-203.
32. Teirstein P: Cypher Compassionate Use - the SECURE Registry. Presented at the Scientific Sessions of the American College of Cardiology, Drug-Eluting Stent Symposium, Chicago, March 29, 2003.
33. Lemos PA, Lee CH, Sianos G, Tanabe K, Degertekin M, Regar E, Smits PC, van der Giessen WJ, van Domburg RT, van den Brand MJBM, de Feyter P, Vos J, Cummins P, Ruiter A, Serruys PW: Sirolimus-Eluting Stent Implantation in the 'Real-World': Initial Results of the RESEARCH Registry. Am J Cardiol 2002;90:6H.
34. Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, Lee CH, Ruiter A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feijter P, van Domburg R, Serruys PW: Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 2003;92:327-329.
35. Lemos PA, Lee C, Degertekin M, Saia F, Tanabe K, Arampatzis CA, Hoye A, van Duuren M, Sianos G, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW: Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-2099.
36. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, McFadden E, Hofma SH, Van Der Giessen WJ, De Feyter PJ, Van Domburg RT, Serruys PW: Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: A clinical and angiographic study. Circulation 2003;108:1927-1929.
37. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, Liistro F, Carlino M, Airoldi F, Chieffo A, Di Mario C: Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-2180.
38. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW: Coronary restenosis after sirolimus-eluting stent implantation: Morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108:257-260.
39. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R: Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384.
40. Liu XS, Hanet C, Vandormael V, Huang YM, De Scheerder I: Study of Anti-restenosis with the BiodivYsio Dexamethasone Eluting Stent (STRIDE) - a multicenter trial. Eur Heart J 2002;23:265.
41. Sousa JE, Serruys PW, Costa MA: New frontiers in cardiology: Drug-eluting stents: Part II. Circulation 2003;107:2383-2389.
42. Serruys PW: ARTS I - the rapamycin eluting stent; ARTS II - the rosy prophecy. Eur Heart J 2002;23:757-759.
43. Kereiakes DJ: Hippocrates revisited: The evidence for drug-eluting stents. Circulation 2003;107:3012-3014.
44. O'Neill WW, Leon MB: Drug-eluting stents: Costs versus clinical benefit. Circulation 2003;107:3008-3011.
45. Lemos PA, Serruys PW, Sousa JE: Drug-eluting stents: Cost versus clinical benefit. Circulation 2003;107:3003-3007.